Navigation Links
Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference
Date:8/4/2009

CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 29th Annual Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009, at 1:00 p.m. ET at the Boston InterContinental Hotel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
2. Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments
3. Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics: From Concept to Implementation Conference
4. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
5. MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
6. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
7. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
8. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
9. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Second Quarter 2009 Financial Results
11. Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014 Follow us ... chromatography or UPLC is a new and ... that involves the use of extremely small-sized ... chromatographic compounds. This highly sensitive qualitative and ... analysis of chromatography samples. UPLC functions on ...
(Date:7/14/2014)... Skin M.D. by ... on Monday, July 14th, located at 45 East ... last all week through Saturday, July 19th, with ... welcomed to attend. The business is owned by ... anti-aging, weight loss services, and sells high-end industry ...
(Date:7/14/2014)... KeyPoint Credit Union is teaming up with ... and one-mile family fun walk. The run begins inside ... finishes inside Levi’s® Stadium. , Over the past five ... Mission City Community Fund. All proceeds benefit education, seniors ... athletes, part-time pavement-pounders and walkers are invited to help ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 T.E.N., ... relationship-marketing firm, announced today that nominations will be ... 2014 Information Security Executive® (ISE®) North America Awards. ... of the Year, which recognizes executives who have ... risk management, data-asset protection, regulatory compliance, privacy and ...
(Date:7/14/2014)... Many people are unhappy with their jawline. ... reduce a “double chin.” A new product that ... go under the knife. Jawflex is a double chin ... tightening the skin in that area and reducing the ... for facial exercise, double chin elimination and sagging jowls. ...
Breaking Medicine News(10 mins):Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... linked to hypertension years later, study finds , MONDAY, ... and Afghanistan who go into combat are more likely ... than those who serve in supporting roles, a new ... appeared to be a unique risk factor for newly ...
... Surging obesity rates have reversed gains, study finds , MONDAY, ... heart disease may be on the wane, experts say, with ... are now in the clear when it comes to heart ... bear much of the blame for the downturn, the researchers ...
... Analysis notes tamoxifen, raloxifene can up chances of other ... Medications given to women at high risk for developing ... drugs carry other health risks, a new analysis suggests. ... at numerous published studies, including randomized clinical trials and ...
... Global meeting ... ... Scientists and Technologists, , ,WHAT: 21st International Radon Symposium , , ,WHEN: September 20-23, ... Station, , ,WHY: Radon remains a serious, global health threat and remains the ...
... 14 Misonix, Inc. (Nasdaq: MSON ), a ... Europe is used for the ablation of tumors and worldwide ... who wishes to remain anonymous, donated the majority of the ... NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement ...
... , LOS ALTOS, Calif., Sept. 14 ... Higgins, PhD has been named Chief Operating ... as InteKrin,s Chief Scientific Officer after joining the Company earlier ... has had increasingly broad operational and strategic responsibility in key ...
Cached Medicine News:Health News:Combat Exposure Tied to Chronic High Blood Pressure 2Health News:Most Adult Americans at Some Risk for Heart Disease 2Health News:Most Adult Americans at Some Risk for Heart Disease 3Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 2Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 3Health News:21st International Radon Symposium 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 3Health News:InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer 2
(Date:7/14/2014)... July 14, 2014  Remedy Informatics, the leading ... delivery and life sciences research, announced that it ... (NPF) to build the first-ever national patient registry ... and pancreatitis. "The National Pancreas Foundation ... that thoughtful and committed organizations can effect upon ...
(Date:7/14/2014)... DIEGO , July 14, 2014  More than any ... their smartphones and tablet computers -- but their eyes don,t. ... have never needed before, and the eye has not evolved ... and what our eyes can do comfortably often results in ... collectively known as Digital Eye Strain. Now ZEISS has invented ...
(Date:7/14/2014)... , July 14, 2014  Celsion Corporation (NASDAQ: ... today that the Company will ring the NASDAQ Stock Market ... New York, NY . ... of the Celsion and EGEN management teams will participate in ... pm ET.  A live webcast will be available at ...
Breaking Medicine Technology:Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 2Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 3
... Feb. 22, 2011 Delcath Systems, Inc. (Nasdaq: ... received a "refusal to file" letter from the U.S. ... Application (NDA) for its proprietary chemosaturation system used in ... liver through the percutaneous intra-arterial administration of melphalan hydrochloride. ...
... Va., Feb. 21, 2011 MicroAire ... endoscopic treatment for carpal tunnel syndrome.  MicroAire,s new ... and blade assembly that allows surgeons to treat ... the patient,s wrist – thereby avoiding full open-hand ...
Cached Medicine Technology:Delcath Systems Receives Refusal to File Letter From FDA 2Delcath Systems Receives Refusal to File Letter From FDA 3Delcath Systems Receives Refusal to File Letter From FDA 4MicroAire Introduces New SlimLine™ ECTR Cannula 2
... Maxim knee system's curved-on-curved articulation maintains ... excellent sizing options for better patient ... alloy plasma spray porous coating, which ... own ArCom processed polyethylene is used ...
... posterior stabilized knee has an advanced ... flange mates with both resurfacing and ... precise, repeatable kinematics and fit with ... reduce wear. Constant cutting guide peg ...
... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results....
Medicine Products: